One way that bacteria resist antimicrobial agents involves 'drug sensors', proteins that bind a range of structurally unrelated antimicrobial drugs and induce expression of multidrug resistance pumps. The basis for drug recognition is now becoming clear from the recently determined crystal structure of a drug sensor.
The emergence of multidrug resistance is undoubtedly the focal point in our current relationship with prokaryotes. Antibiotic resistance is nothing new and has evolved in bacteria over the millennia of fighting a chemical war first with each other, and then with fungi and plants. What is new is our realization of the ease with which a particular pathogen is able to recruit drug resistance from outside sources. Important new insights into one key drug resistance mechanism have come from the recently determined crystal structure of a protein capable of sensing a wide range of antimicrobial drugs and inducing expression of protein pumps that act to rid the cell of the drug molecules.
The instant acquisition by a bacterial cell of resistance to five or six different antibiotics initially seemed like breaking of all the rules. It is implausible that five mutations could arise simultaneously -at a rate of 10 -7 per mutation, the probability of this happening would be (10 -7 ) 5 or 10 -35 . The riddle was solved when it was found that cells can pick up a plasmid that confers resistance to five antibiotics. This finding seemed to set the stage for an intelligent solution to the problem of drug resistance. It is reasonable to expect that resistance mechanisms have evolved for each and every natural antimicrobial compound. This means that, sooner or later, the resistance mechanism will move from its unknown host onto a plasmid and into a human pathogen.
One solution to this problem would be to make synthetic antibiotics that would not be subject to pre-existing resistance mechanisms. This is not a foolproof strategy, as the bacterial protein targeted by the synthetic antibiotic would still be subject to mutation -but such a mutation might decrease the fitness of the organism. More importantly, one might expect that a synthetic drug would not be subject to the very potent specific resistance mechanisms bacteria have evolved, such as the enzymes that destroy natural antibiotics -for example, β-lactamase cleaves penicillins and acetyl transferase modifies aminoglycosides -or the transmembrane pumps that extrude them from the cell -such as the tetracycline extrusion pump.
This logic proved simplistic when multidrug resistance pumps were discovered in bacteria [1] [2] [3] [4] [5] . These membrane proteins extrude a variety of chemically unrelated antimicrobial agents from the cell. As they do not rely on structure recognition in selecting their substrates, it is not surprising that multidrug resistance pumps extrude artificial antimicrobial agents perfectly well. For example, clinical resistance to synthetic quinolones in Pseudomonas aeruginosa is largely due to the expression of the MexAB-OprM pump [6] .
With multidrug resistance pumps, bacteria might have hit upon a design for a 'perfect defense'. If a multidrug resistance pump can extrude any toxin from the cell, then bacteria already have in their possession a powerful defense mechanism against the future wonder drugs that are moving through the pipe-lines of combinatorial chemistry programs. The multidrug resistance pumps are especially effective in gram-negative bacteria, where they extrude toxins across the outer membrane. The outer membrane of a gram-negative bacterial cell is a good barrier for amphipathic antimicrobial agents, and the synergy between a restrictive barrier to permeation and efflux across this barrier is what turns the gram-negative multidrug resistance pumps into a potent defense mechanism.
How can a single protein extrude chemically unrelated drugs and also distinguish them from all cellular molecules? This seemingly impossible task could be accomplished if the protein recognizes primarily polarity, rather than structure. Antibiotics with intracellular targets have to be amphipathic molecules in order to cross the membrane. Cellular compounds, on the other hand, have to be hydrophilic in order to stay in the cell. A protein with a large amphipathic pocket could selectively bind the more hydrophobic toxins and ignore the cellular compounds.
One can marvel at the inventiveness of nature in producing multidrug resistance pumps. But one can, and in fact should, also consider the likelihood of nature being less than perfect in this respect. This thinking is behind the notion of a 'sloppy translocase' [7] , which holds that each multidrug resistance pump evolved to protect the cell from a particular antibiotic, but that the proteins are not very specific, leading to the 'multidrug resistance' phenomenon. It is not obvious that this is a falsifiable hypothesis -how do you test for unknown natural compounds? -but this does not make it any less probable.
The first evidence against the sloppy translocase model came from the finding by Ahmed et al. [8] of a transcriptional activator that controls the expression of the Bmr multidrug pump in a gram-positive Bacillus subtilis. Antimicrobial substrates of the Bmr pump, such as rhodamine or tetraphenyl phosphonium, induce the expression of the gene encoding the pump protein ( Figure 1 ). This induction is mediated by the BmrR regulator, which was shown to bind many of the various substrates of the pump and activate transcription of its gene. It appeared that the cell uses a special multidrug sensor to detect the presence of potential toxins. This detection leads to increased production of the pump that extrudes toxins from the cell. The existence of a multidrug sensor suggests that Bmr is a specialized multidrug pump after all.
Another multidrug sensor was discovered in the course of our studies of the adaptation of Escherichia coli to uncouplers of oxidative phosphorylation. These synthetic compounds are protonophores that collapse the cell's proton motive force. Natural protonophores are not known, yet cells clearly demonstrated an ability to adapt to a variety of these substances. A search for the mechanism of this adaptation led to the cloning of the gene encoding the EmrAB multidrug pump [3] . Subsequent studies showed that the pump is induced in the presence of protonophores and the weak acid salicylate. The induction is controlled by the EmrR multidrug sensor, which is a repressor of the emrAB operon [9] . The EmrR protein belongs to the MarR family of repressors and is a helix-turn-helix type DNAbinding protein. It exists in the form of a dimer, and the pure protein binds substances such as dinitrophenol, CCCP and FCCP with micromolar affinity.
The third known multidrug sensor was discovered by Skurray and colleagues [10] , who were studying the QacA multidrug resistance pump in the pathogen Staphylococcus aureus. QacA belongs to the same 'major facilitator' family of drug antiporters as Bmr, and also extrudes hydrophobic cations from the cell. QacA helps S. aureus resist cationic antiseptics such as benzalkonium chloride and chlorhexidine. QacA substrates were found to induce the pump, and the regulator was identified as a transcriptional repressor of the TetR family. QacR binds many of the cationic substrates of QacA and is released from the DNA. A related TetR repressor binds tetracycline and controls a specific tetracycline efflux pump. Interestingly, although QacR has the same function as the drug sensor BmrR, binds a similar spectrum of ligands and regulates a related pump, it shows no similarity to BmrR.
The drug sensors are providing us with useful insights into the functions of multidrug resistance pumps and will undoubtedly be very useful in searching for natural multidrug resistance pump substrates. There is another area where the drug sensors can make a significant impact on our understanding of the phenomenon of multidrug resistance. Much effort has been expended on understanding the mechanism of multidrug resistance pumps, and much useful information has been obtained. The inevitable limitation of these studies has been the lack of good structural methods to access the tertiary structure of the complex membrane proteins. The drug sensors share an important feature with the larger transporters they regulate, which is the remarkable ability to discriminate between drugs and self molecules. Understanding how the small regulators do this will be very useful in helping to decipher the workings of the pumps.
Structure of the BmrR drug-binding site
The most interesting part of a multidrug resistance pump is of course its drug-binding site, and this is undoubtedly also true of the drug sensors. A distinct domain assignment has been made for proteins like BmrR, which belong to the MerR family of transcriptional activators. These proteins all have a similar amino-terminal DNA-binding domain, but show little homology in their carboxy-terminal, apparently ligand-binding domain. This helped to further 'simplify' BmrR for structural studies. An 18 kDa carboxy-terminal fragment retained the ability of the native 32 kDa protein to form dimers and bind ligands. This ligand-binding fragment was successfully crystallized, and its three-dimensional structure has recently been reported by Zheleznova et al. [11] . At last, one can gaze into a binding site that accommodates structurally unrelated drugs.
The first impression from looking at the crystal structure of the BmrR fragment is that there is no binding site within the compact structure of the folded protein. The binding site revealed itself, at 2.8 Å resolution, when the BmrR fragment was crystallized with the ligand tetraphenylphosphonium (TPP) (Figure 2 ). Apparently, one of the protein's α helices gates an opening into a hydrophobic pocket. The ligand displaces the α helix and enters the pocket. Interestingly, this process involves the melting of the α helix. This could potentially cause a large conformational change in the protein, resulting in untwisting of the bound DNA and properly positioning the promoter sequences recognized by RNA polymerase.
Once inside the binding site, TPP interacts with a series of hydrophobic residues that make up its surface. The phenyl rings of TPP form van der Waals contacts with the side chains of isoleucine, valine and alanine, and at least one of the rings stacks against a tyrosine residue. The bottom of the pocket contains an unusually positioned glutamate residue, buried in a hydrophobic environment and forming hydrogen bonds with tyrosine residues. One of the rings of TPP -which carries part of the delocalized positive charge -contacts this glutamate.
TPP binds BmrR with a modest dissociation constant (Kd) of 100 µM; rhodamine binds much more tightly (Kd = 1 µM), but efforts to crystallize the BmrR fragment with this much better ligand were unsuccessful. One might expect that a protein should crystallize better with a ligand that forms a tighter bond. The questions of why this is not the case will have to wait for the art of growing crystals to transform itself into an exact science. For now, one can look at an in silico model the authors constructed by replacing TPP with rhodamine. Zhelznova et al. [11] found that the very different molecule rhodamine fits into the same pocket as TPP. The charged nitrogen of rhodamine forms a closer contact with glutamate, which would explain the tighter binding.
The structure of the binding site of BmrR does look distinctly different from a typical binding pocket of a receptor or an enzyme. It can be roughly approximated by a cone with a hydrophobic inner surface and a negative charge at the tip. Two main components generally ensure tight and specific ligand binding: polar interactions with tightly fitting groups of the protein and the ligand, and a general stereospecific match with the binding pocket. Both types of interaction are conspicuously absent in the BmrR-ligand complex. It seems that the hydrophobic cone will accommodate a large number of hydrophobic molecules, the affinity being determined by the ionic interaction with the glutamate and the relative surface contact and stacking between the hydrophobic groups of the ligand and the binding site. To put it plainly, BmrR seems to have been designed to discriminate molecules largely on the basis of polarity.
Why hydrophobic cations?
Functional studies and structural analysis both suggest that BmrR evolved to detect chemically unrelated hydrophobic cations. This seems to make sense, given that hydrophobic cations are substrates of the Bmr pump that BmrR regulates. Interestingly, hydrophobic cations are the only substrates for small multidrug resistance pumps of the SMR family, are preferred substrates for most multidrug resistance pumps of the MF and ABC families, and are among the substrates of the versatile RND family of multidrug resistance pumps. Hydrophobic cations are also preferred substrates for the P-glycoprotein multidrug resistance pump, a member of the ABC family that is responsible for multidrug resistance of human tumors [12] . This makes understanding the binding and extrusion of cationic substances highly significant.
Did multidrug resistance pumps and their sensors originally evolve to combat cationic antimicrobial agents? We know of many very effective cationic antimicrobial agents, potent antiseptics such as benzalkonium chloride and ethidium bromide. The problem is, all these compounds are synthetic and not a single known natural antibiotic is a hydrophobic cation. This is especially surprising considering that a positive charge on a molecule will increase its accumulation in the bacterial cell. The membrane of a bacterial cell is charged by proton pumps and maintains a ∆Ψ of about 120-180 mV. According to the Nernst equation, there is a 10-fold accumulation of a cation for every 60 mV of the membrane potential. This means that an antibiotic carrying a positive charge will accumulate in the cell 100-1000-fold, and will be that much more potent than a similar neutral molecule. (Many natural compounds are weak bases that form cations upon protonation but these only penetrate in the neutral form and are extruded from the cell by the pH gradient, which does not make them good antibiotics.)
The fact that amphipathic cations are conspicuously absent from known natural antibiotics is especially puzzling given that they are the preferred substrates for most multidrug resistance pumps. We have argued that it is precisely the existence of multidrug resistance pumps that is responsible for this apparent paradox [13] . If multidrug resistance pumps evolved in response to natural antimicrobial amphipathic cations, then these substances would be difficult to discover in standard screens that employ cells carrying multidrug resistance pumps. In the process of drug discovery, the concentration of antimicrobial agents is prone to be low, and multidrug resistance pump substrates will be overlooked.
For this reason, we suggested that cells with mutations abolishing the function of their multidrug resistance pumps could be used to increase the sensitivity of screens for new antimicrobial agents. While using such mutants is a reasonable, if somewhat unpredictable, way to discover possible cationic antimicrobial agents, another approach is to search for possible substrates of multidrug resistance pumps among known compounds. Many natural substances have been described as a result of systematic chemical analysis of organisms, rather than in particular bioassay-driven purifications. One would then look for substances that are amphipathic cations of natural origin that have little or no antimicrobial activity.
Using these criteria, we identified a group of plant alkaloids whose members have little or no antimicrobial activity. These are the berberine alkaloids, which are widely spread among the plant world and are found among many Ranunculales species, for example. These substances bear a resemblance to artificial substrates of multidrug resistance pumps, such as ethidium bromide or benzalkonium chloride. They are amphipathic and have a positive charge which is delocalized by the conjugated ring structure, an essential feature of a good permeant cation.
It is interesting to note in this regard that synthetic hydrophobic cations were originally introduced into experimental studies as probes to measure the membrane potential across cells and organelles [14] . This ingenious approach made it possible to measure the membrane potential (∆Ψ) of objects comparable in size to a microelectrode. By measuring the concentration of the cation after accumulation into a cell or an organelle, the membrane potential could be calculated from the Nernst equation. It was argued that using synthetic molecules such as TPP insulated this approach from possible interference by substrate translocases, which one would not expect to recognize these foreign substances. This logic worked well in the case of mitochondria, and measurements of ∆Ψ in these organelles went a long way in supporting Mitchell's chemiosmotic theory. The use of this method with bacteria, as we can now see is problematic. B. subtilis, for example, will detect TPP with BmrR and induce production of the Bmr pump that will extrude TPP, messing up the results of ∆Ψ measurements.
Berberine alkaloids appeared to be good substrates for the NorA multidrug resistance pump [13] and for the QacA multidrug resistance pump of S. aureus. Mutations knocking out multidrug resistance pumps were found to turn berberine, for example, into a very strong antibiotic. It seems that this group of positively charged cations, which are spread very widely in the plant world, are typical of the cationic antimicrobial agents that the multidrug resistance pumps evolved to counter. Berberine alkaloids do not, however, bind to the Bmr pump (A.A. Neyfakh, personal communication). Neither does ethidium bromide, which is a good substrate of the BmrR.
Both ethidium and berberine are planar molecules, whereas the good ligands for BmrR, such as rhodamine, are not. Planar molecules would bind very well to a slit-shaped pocket, but would not produce high-affinity interaction with a cone-shaped binding site of BmrR. The Bmr pump, like other multidrug resistance pumps, extrudes both planar and aplanar hydrophobic cations perfectly well. This probably suggests that the multidrug resistance pump has a flexible hydrophobic binding pocket that will properly envelope the incoming toxin. The QacR sensor binds both the planar ethidium bromide and the aplanar rhodamine, also suggestive of a more accommodating, 'hand-glove' type of flexible interaction with ligands. Not so with BmrR, where the rigid binding pocket sets certain restrictions on shape and size, and will exclude poorly interacting planar molecules. What are these cationic toxins that BmrR steers towards its less discriminating pump?
